Synapse - Dean Bajorin

Results (660)

Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma

Meeting Abstract

Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma

Journal Article

Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
ESMO Open (2025)

Fulltext@MSK | Save

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Journal Article

Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274

Meeting Abstract

Milowsky, M. I.; Galsky, M. D.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)

Meeting Abstract

Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma

Meeting Abstract

Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Circulating tumor DNA and response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled in CALGB 90601 (Alliance)

Journal Article

Guercio, B. J.; Whiting, K.; Shah, R. H.; Ballman, K. V.; Halabi, S.; Regazzi, A. M.; Milbank, J. H.; Bajorin, D. F.; Beltran, H.; Morris, M. J.; more...
European Urology Open Science (2025)

Fulltext@MSK | Save

Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from CheckMate 274

Journal Article

Galsky, M. D.; Witjes, J. A.; Gschwend, J. E.; Milowsky, M. I.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save